Req ID:  96031

Ballina, IE, F26D786

For 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. In return, we’ll help you build a career that you can feel passionate about.


We are seeking an experienced Analyst for our Analytical Services Department located in Ballina, Co. Mayo. You shall be reporting to the Analytical Services Department Manager.


This role shall be responsible for the following:


  • Conduct in-vitro and ex vivo assays in both an R&D and GMP environment.
  • Assist in the development and validation of different immunoassays (ELISA, Western Blot, ELISPot etc.) and activity based assays.
  • Generation of GMP compliant Data capture forms, SOPs, Protocols and reports.
  • Carry out data calculations and simple statistics.
  • Assist in internal, regulatory and client visits/audits and respond to findings
  • Sourcing, purchasing and stocking consumables, standards and reagents required for testing.


The following are minimum requirements related to the Technical Analyst position.


  • A degree (minimum) in a relevant science discipline.
  • 2-3 years’ experience of working in a GMP environment
  • Must be proficient in Microsoft package particularly Excel.
  • Excellent communication skills
  • Must be able to work as both part of a team and on his/her own initiative
  • Experience in the conduct of cell based assays an advantage.


About Biologics Testing Solutions
With more than 50 years of experience and proven regulatory expertise, the Charles River Biologics group can address challenging projects for biotechnology and pharmaceutical companies worldwide. Offering a variety of services such as contamination and impurity testing, protein characterzation, bioassays, viral clearance studies and stability and lot release programs, we support clients throughout the biologic development cycle, from the establishment and characterization of cell banks through preclinical and clinical studies to marketed products. Whether clients need stand-alone services, a unique package of testing, or insourced support, our Biologics group can create a custom solution to suit their needs.  Each year more than 20,000 biologic testing reports are sent each and over 200 licenses products are supported by our biologics testing solutions team.


About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.


With over 13,000 employees within 80 facilities in 23 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges.  Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world.


At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of 80% of the drugs approved by the FDA in 2017.


For more information, please visit